Uptime’s 15 th Annual Global Data Center Survey Results Show Both Commitment and Hesitancy as Industry Plans for Wider AI Usage, Climate Change Reporting, and the NVIDIA Revolution to Come
30.7.2025 12:02:00 CEST | Business Wire | Press Release
Uptime Institute today announced the release of its 15th Annual Global Data Center Survey 2025 revealing an innovative and resilient industry – one that is also facing rising costs, worsening power constraints, and challenges in meeting the demands for AI. As operators expand and modernize to meet power and density requirements, they must address availability, efficiency, staffing challenges, supply chain delays, and unpredictable technological advances.
“Our data shows operators are tasked with managing a lot of big strategic challenges at the same time. These include anticipating multiple technological changes, planning for expansion in spite of major constraints on power availability, and preparing for and supporting unpredictable AI workload demand,” said Andy Lawrence, Executive Director of Research, Uptime Institute. “This is a time where senior level experience is critical. But for the first time, more operators are finding it harder to recruit and retain senior people than people at an earlier stage of their career. There is a management shortage, with many experienced leaders retiring just as another phase of dramatic growth gets underway.”
Roughly one-third of data center owners and operators currently perform some AI training or inference, and a significantly greater proportion plan to do so in the future. But much of this is early stage and cautious. Uncertainty over the appropriate or likely venues for AI workloads, and apprehension over the power demands of projected NVIDIA GPU systems, is likely contributing to capacity concerns.
Now in its 15th year, Uptime Institute’s annual survey is the most comprehensive and longest-running study of its kind. The findings of this report highlight the practices and experiences of data center owners and operators in the areas of resiliency, sustainability, efficiency, staffing, cloud, and artificial intelligence.
Key findings from the 2025 report include:
- Cost issues remain the top concern for digital infrastructure management teams in 2025 — but worries around forecasting future capacity requirements have grown significantly.
- Average PUE levels show little change for the sixth consecutive year, with improvements constrained by legacy infrastructure and some climate specific limitations to efficient cooling.
- Average server rack power densities continue to rise, with greater adoption of racks in the 10–30 kW range. Few facilities exceed 30 kW, and extreme densities are as yet rare.
- The collection and reporting of key sustainability metrics have not improved in 2025, which is likely due in part to commercial pressures to support AI, and easing regulatory pressure in some regions.
- Trust in AI for data center operations depends on the use case: most would allow its use for analyzing sensor data and predictive maintenance tasks, but not configuration changes, controlling equipment, or staffing issues.
- Impactful data center outages are gradually becoming less frequent — but one in ten still cause serious or severe disruption, underscoring the need for continued investment.
- Enterprises continue to adopt hybrid IT strategies, spanning cloud, colocation on-premises data centers. On-premises data centers remain foundational for those with large, mission critical processing needs, with 45% of IT workloads still residing in corporate facilities.
- Staffing challenges persist in 2025. Nearly two-thirds of operators report difficulty retaining staff, finding qualified candidates, or both.
About the Survey:
Uptime conducted this year’s Annual Global Data Center Survey online and via email from April to May 2025 and collected responses from more than 800 data center owners and operators. For the third consecutive year, Uptime’s survey asked data center operators to identify their management team’s top concerns related to digital infrastructure. In 2025, new response options were added to reflect the evolving challenges surrounding power availability, supply chain disruptions, and demand for AI.
The survey participants represent a wide range of industry verticals in multiple countries. Nearly half (43%) are located in North America and Europe. Approximately one in five respondents work for professional IT / data center service providers — that is, staff with operational or executive responsibilities for a third-party data center, such as those offering colocation, wholesale, software, or cloud computing services.
Learn More:
Download the executive summary report here and register for the webinar here covering key trends and takeaways from the survey results on July 30th at 9:00 AM PDT (9:00 AM PDT, 12:00 PM EDT, and 5:00 PM BST). To join our Uptime Institute Bright Talk Channel, go to https://www.brighttalk.com/join/.
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. With over 3,500 awards issued in over 118 countries around the globe, and over 1,100 currently active projects in 80+ countries, Uptime has helped tens of thousands of companies optimize critical IT assets while managing costs, resources, and efficiency. For over 30 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their individual business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. Offerings include the organization’s Tier Standard and Certifications, Management & Operations reviews and assessments including SCIRA-FSI financial sector risk assessment, the Sustainability Assessment, and a broad range of additional risk management, performance, availability, and related offerings. Uptime Education training programs have been successfully completed by over 90,000 data center professionals, such as the much-valued ATD (Accredited Tier Designer) and AOS (Accredited Operations Specialist). The Uptime Education curriculum has been expanded by the acquisition of CNet Training Ltd. in 2023.
Uptime Institute is headquartered in New York, NY, with offices in London, Sao Paulo, Dubai, Riyadh, and Singapore, and full-time Uptime professionals based in over thirty-four countries around the world. For more information, visit uptimeinstitute.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250730149641/en/
Contacts
Media contact:
Brenda South
Publicrelations@uptimeinstitute.com
206-706-6467
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom